About Clinical Trial Optimization
The Clinical Trial Optimization category is part of the AI Drug Discovery market map, tracking 13 companies building in this segment. Target discovery, molecular design, protein folding, and clinical trial optimization accelerating the path from lab to patient. Curated by Hartmann Capital's venture research team.
Companies in Clinical Trial Optimization
- Unlearn.AI — Series C, $130M
- ConcertAI — Series C, $300M
- Saama Technologies — Growth, $75M
- Medable — Series D, $521M
- Deep 6 AI — Series A, $17M
- AiCure — Series B, $32M
- TrialSpark — Series B, $120M
- Antidote Technologies — Series A, $14M
- Medidata (Dassault) — Acquired
- Clinerion — Growth, $10M
- BioPhy — Seed
- Huma — Series D, $300M
- H1 — Series C, $100M
Frequently Asked Questions
- What companies are in the Clinical Trial Optimization category?
- The Clinical Trial Optimization category includes 13 companies: Unlearn.AI, ConcertAI, Saama Technologies, Medable, Deep 6 AI, AiCure, TrialSpark, Antidote Technologies, Medidata (Dassault), Clinerion, BioPhy, Huma, H1. This is part of the AI Drug Discovery market map maintained by Hartmann Capital.
- How many Clinical Trial Optimization startups are tracked?
- Hartmann Capital tracks 13 companies in the Clinical Trial Optimization segment of the AI Drug Discovery market map.
- What are the best funded Clinical Trial Optimization companies?
- Top funded companies in Clinical Trial Optimization include Medable ($521M), ConcertAI ($300M), Huma ($300M), Unlearn.AI ($130M), TrialSpark ($120M). Browse the full list in the AI Drug Discovery market map.
- How can I submit my startup?
- You can submit your startup for inclusion by visiting the submission page. Submissions are reviewed by Hartmann Capital's research team.